All News

LOS ANGELES-Researchers at the AIDS Institute of UCLA have identified an HIV gene that appears to play a role in HIV immunosuppression by inhibiting reproduction of CD4+ T cells

MARINA DEL REY, Calif-A detailed financial analysis of the costs associated with chemotherapy delivery showed home health care costs to be, on average, 2.5 times higher than those incurred in an outpatient clinic setting, said Patrick A. Grusenmeyer, MPA, financial administrator for the Ochsner Cancer Institute, New Orleans.

New research that is bringing ribozyme therapy closer to clinical trials was presented at the recent meeting of the American

SAN FRANCISCO-Two separate clinical trials have demonstrated that triple combination antiretroviral therapy maintains its superiority over double therapy in the extended treatment of HIV infection, although neither study included clinical morbidity as an endpoint.

Eventually, maybe within 2 years, oncology specialists will become the primary-care physicians for patients diagnosed with

Population growth is adding to the threat of massive epidemics, two Stanford scientists told a meeting at the Beijer Institute of

SAN FRANCISCO-Amphotericin B lipid complex may be the treatment of choice for patients with hematogenous or invasive candidiasis, Elias J. Anaissie, MD, said at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

RTOG 91-11, a National Cancer Institute high priority laryngeal preservation protocol, has been streamlined and the accrual

By taking the initiative and addressing concerns about patient care and conservation of health-care resources, nursing staff at

MARINA DEL REY, Calif-Every physician needs to know the value of his or her practice, especially in this era of change-when mergers, affiliations, partner buy-ins or buy-outs, and outright sales of practices are common, Kim R. Johnson, RN, said at the annual conference of the Association of Community Cancer Centers (ACCC).

MARINA DEL REY, Calif-In today's health care environment, the providers of cancer care must determine not only how to market their services but also whom to market them to, Patti A. Jamieson, MSSW, MBA, said at the annual Conference of the Association of Community Cancer Centers (ACCC).

To adress questions relative to the safety of the blood supply ,the National Heart,Lung and Blood Institute, together

SILVER SPRING, Md-The FDA's Oncologic Drugs Advisory Committee (ODAC) has voted 6 to 0 with one abstention to recommend that Rhône-Poulenc Rorer's Taxotere (docetaxel) be approved for the treatment of patients with anthracycline-resistant locally advanced or metastatic breast carcinoma.

MARINA DEL REY, Calif-Representatives of the American Association of Community Cancer Centers (ACCC), an organization of almost 500 cancer institutions, presented the group's Award for Outstanding Achievement in Clinical Research to Rodger J. Winn, MD, at their annual economics conference.

Patients with advanced cancer or AIDS are frequently bothered by anorexia, decreased food intake, fatigue, weight loss, muscle wasting, and a decline in functional status. Nutritional support may afford these patients a

Control of chemotherapy-induced nausea and vomiting is a major concern for patients receiving cancer therapy and a major quality of life issue. However, the fact that antiemetic control improves quality (but not duration) of

WASHINGTON-Programs designed to encourage drug addicts not to share needles can help reduce the spread of HIV, a National Academy of Sciences panel said in its report to Congress. The report may pave the way for a change in government policy to allow the use of federal funds to support such programs.

WASHINGTON-US spending on research and development has fallen over the last 20 years from 3% to 2.6% of the Gross Domestic Product, and the United States now ranks behind Japan and Germany in R&D spending, according to a study released by the Institute for the Future, a California-based think tank sponsored by 23 research-oriented pharmaceutical companies.

BALTIMORE-Although standard imaging methods are not sensitive enough to catch early-stage pancreatic tumors, positron emission tomography (PET), currently under investigation for this purpose, may prove to be a useful addition to CT scans, said Karl F. Hubner, MD, professor of radiology, University of Tennessee Medical Center, Knoxville. Dr. Hubner spoke, along with Pankaj Jay Pasricha, MD, at a meeting on nuclear medicine sponsored by the Johns Hopkins Medical Institutions.

BALTIMORE-The advent of spiral CT offers advantages over regular CT scans, Elliot K. Fishman, MD, said at a conference sponsored by the Johns Hopkins School of Medicine, where he is professor of radiology and oncology.

PARIS-Rhône-Poulenc Rorer Inc.'s Campto (irinotecan/CPT-11), the first new therapeutic agent for the treatment of colorectal cancer since the introduction of fluorouracil nearly 40 years ago, is now available in France. France is the first country outside Japan to approve this agent for marketing.

MONTREAL-The newest beta-lactam plus beta-lactamase inhibitor combination, piperacillin/tazobactam (Zosyn), when combined with amikacin, is highly effective for empiric treatment of patients with febrile granulocyto-penia, Jean A. Klastersky, MD, said at the 19th International Congress of Chemotherapy. He was speaking at a symposium sponsored by Lederle/Wyeth-Ayerst International, manufacturer of Zosyn.

Last January, 13 of the nation's foremost cancer centers formed the Na-tional Comprehensive Cancer Network (NCCN), an alliance that spans the nation geographically, with the goal of providing high-quality cost-effective medical services to cancer patients across the country.

SEATTLE-Improvements in standard imaging techniques may lead toenhanced prostate cancer detection and local staging accuracyin the near future, Gary Sudakoff, MD, said at the Pacific NorthwestCancer Foundation Meeting on Transperi-neal Brachytherapy forEarly Stage Prostate Cancer. Such methods may include combiningcolor Doppler imaging with endorectal ultrasound (see image )and using new types of coils with magnetic resonance imaging (MRI),said Dr. Sudakoff, of the University of Chicago.

It is by now axiomatic that information is vitally important in a managed care environment. Whether you are preparing for participation with managed care plans, beginning to evaluate the results of ongoing participation, considering expansion of existing managed care arrangements, or assessing capitation, you will need a plan.

MONTREAL-In a small Canadian study of patients with cancer-related pain, nearly 75% said that 12-hour dosing with sustained-release morphine sulfate tablets (MS Contin) offers advantages over 8-hour dosing, and nearly all (94.5%) preferred 12-hour to 4-hour dosing, report Gérard G. Mignault, MD, and colleagues from the Hôtel-Dieu de Mon-tréal and Purdue Frederick, Pickering, Ontario, manufacturer of MS Contin.

MONTREAL-Altering genes to express therapeutic cytokines may represent an improved approach to direct delivery of these increasingly utilized recombinant proteins, Michael T. Lotze, MD, said during a plenary session at the 19th International Congress of Chemotherapy (ICC).

NEW YORK-Many cancer patients struggling to return to normal life still believe in the John Wayne school of psychotherapy: "Tough it out, stranger," quipped Allen Levine, ACSW, at a symposium on fatigue and cancer, sponsored by Cancer Care, Inc.

NEW YORK-Although 90% of prostate cancer patients in a Harris poll cited delay of disease progression as a key benefit they seek from a therapy, only one third of physicians said they would be very likely to recommend complete hormonal therapy (CHT) (an oral antian-drogen drug plus castration therapy) for all of their stage D patients. Nearly all physicians said they discuss CHT with patients, but more than 50% of patients said it had not been presented as a treatment option. The poll was sponsored by the advocacy group US TOO! and funded by Schering Oncology/Biotech.

PHILADELPHIA-The American Association for Cancer Research (AACR) is sponsoring its fourth annual Gertrude Elion Cancer Research Award. This award, provided through an educational grant from Glaxo Wellcome Oncology, is open to nontenured cancer investigators in clinical, basic, or translational research in the United States and Canada.